tovorafenib 300 MG Powder for Oral Suspension [Ojemda]
Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
tovorafenib 300 MG Powder for Oral Suspension [Ojemda]
300 MG · Powder for Oral Suspension · oral
A form of tovorafenib →
tovorafenib 300 MG Powder for Oral Suspension [Ojemda] — B-Raf serine-threonine kinase (BRAF) inhibitors. Strength, form, class, interactions & more.
![tovorafenib 300 MG Powder for Oral Suspension [Ojemda]](https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ea3a9631-3a66-6a7c-e053-2995a90ae2ad&name=ojemda-01.jpg)
Active ingredient
Classification
B-Raf serine-threonine kinase (BRAF) inhibitorsKinase Inhibitor
Drug interactions
Tovorafenib has several drug interactions that may affect its efficacy and safety.
- majorstrong or moderate CYP2C8 inhibitors — increased risk of adverse reactions
- majorstrong or moderate CYP2C8 inducers — reduced effectiveness of OJEMDA
- majorhormonal contraceptives — risk of contraceptive failure and/or increased breakthrough bleeding
- majorcertain CYP3A substrates — serious therapeutic failures
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication